Eloxx Pharmaceuticals, Inc. (ELOX): Nasdaq/NYSE listing notice — Eloxx receives Nasdaq delisting notice; trading suspended Oct 16, shares to OTC

Eloxx Pharmaceuticals, Inc.

Nasdaq notified Eloxx on Oct 12, 2023 that it failed to regain compliance with $35M MVLS rule.
Trading of common stock (ELOX) suspended on Nasdaq effective Oct 16, 2023; will trade OTC under same symbol.
Company intends to request review by Nasdaq Listing Council, which stays delisting filing but not suspension.
Previously granted extensions expired Oct 9, 2023; stock has been below compliance threshold for over a year.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Eloxx Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: market value
Rules: 5550(b)(2)

Exact text from the filing

October 12, 2023, Eloxx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), received a determination letter (the “Delisting Notification”) from the staff (the “Staff”) of the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that Nasdaq will suspend trading in the Company’s common stock, par value $0.01 per share (the “Common Stock”), effective at the opening of trading on October 16, 2023, because the Company had not regained compliance with the Nasdaq Listing Rule 5550(b)(2) (the “Listing Rule”), which requires a listed company to have at least $3

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Eloxx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-109423

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.